Abstract
Castration-resistant prostate cancer (CRPC) is defned as prostate cancer that no longer responds to androgen deprivation therapy. At the genome level, CRPC is a heterogeneous disease that is marked by a range of genetic and epigenetic lesions. These lesions differ from patient to patient, but have common pathway-based themes. Clinically, a range of phenotypic presentations or subtypes of CRPC are observed that mirror this underlying heterogeneity as the disease progresses; each phenotype carries a different prognosis and different implications for treatment. In this review, we discuss the clinical subtypes of CRPC based on histology; the presence of metastatic disease and pattern of spread; patient-reported symptoms; and levels of biomarkers, such as serum bone turnover biomarkers, prostate-specific antigen, circulating tumor cell enumeration, and neuroendocrine biomarkers. We then address the potential relationship between these clinical phenotypes (with their underlying molecular subtypes) and therapeutic decision-making and prognosis, as well as ongoing research strategies.
Original language | English (US) |
---|---|
Journal | Clinical Advances in Hematology and Oncology |
Volume | 11 |
Issue number | 11 |
State | Published - Nov 2013 |
Externally published | Yes |
Keywords
- Androgen receptor
- Castration-resistant prostate cancer
- Clinical phenotype
- Genotype
- Neuroendocrine prostate cancer
- Prognosis
ASJC Scopus subject areas
- Hematology
- Oncology